Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 300-4820 Richard Rd SW CALGARY AB T3E 6L1 |
Tel: | N/A |
Website: | https://www.resverlogix.com |
IR: | See website |
Key People | ||
Donald J. Mccaffrey Chairman of the Board, President, Chief Executive Officer, Secretary | A. Brad Cann Chief Financial Officer | Jan O. Johansson Senior Vice President - Medical Affairs |
Michael T. Sweeney Senior Vice President - Clinical Development | Ewelina Kulikowski Chief Scientific Officer |
Business Overview |
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. |
Financial Overview |
For the fiscal year ended 31 December 2023, Resverlogix Corp revenues was not reported. Net loss increased from $3.6M to $16.7M. Higher net loss reflects Loss (gain) on change in fair value of r decrease from $7M (income) to $9.6M (expense), FV Adjustments of Financial Investments decrease of 85% to $580K (income), Investment tax credits decrease of 48% to $57K (income). |
Employees: | 18 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $24.27M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$6.11M as of Dec 31, 2023 |
Net annual income (TTM): | -$22.93M as of Dec 31, 2023 |
Free cash flow (TTM): | -$4.19M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $9.24M as of Dec 31, 2023 |
Shares outstanding: | 274,295,571 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |